MARINELLI, SARA
 Distribuzione geografica
Continente #
NA - Nord America 253
EU - Europa 89
AS - Asia 82
OC - Oceania 6
SA - Sud America 3
AF - Africa 2
Totale 435
Nazione #
US - Stati Uniti d'America 245
CN - Cina 41
FR - Francia 23
IT - Italia 21
JP - Giappone 12
IE - Irlanda 10
DE - Germania 9
CA - Canada 8
BG - Bulgaria 7
IN - India 7
AU - Australia 5
NL - Olanda 4
TR - Turchia 4
ES - Italia 3
HK - Hong Kong 3
IR - Iran 3
VN - Vietnam 3
AE - Emirati Arabi Uniti 2
AR - Argentina 2
BE - Belgio 2
CZ - Repubblica Ceca 2
GB - Regno Unito 2
SE - Svezia 2
SG - Singapore 2
TW - Taiwan 2
CL - Cile 1
DZ - Algeria 1
FI - Finlandia 1
KR - Corea 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
RO - Romania 1
RU - Federazione Russa 1
TH - Thailandia 1
UA - Ucraina 1
ZA - Sudafrica 1
Totale 435
Città #
Ashburn 27
Fairfield 24
Santa Cruz 16
Seattle 14
Houston 13
Boardman 11
Buffalo 11
Dublin 10
Chicago 8
Bologna 7
Sofia 7
Woodbridge 7
Cambridge 6
Columbus 6
Wilmington 6
Tokyo 5
Beijing 4
Guangzhou 4
Mumbai 4
Shanghai 4
Sydney 4
Tappahannock 4
Bremen 3
Chengdu 3
Dong Ket 3
Hayamiya 3
Medolla 3
New York 3
Amsterdam 2
Basking Ridge 2
Bethesda 2
Brussels 2
Buenos Aires 2
Crugers 2
Kyoto 2
Maltepe 2
Mountain View 2
Ottawa 2
Paris 2
Phoenix 2
Riva 2
Rome 2
San Diego 2
Stockholm 2
Andria 1
Ankara 1
Ann Arbor 1
Atlanta 1
Auckland 1
Bangkok 1
Batna City 1
Berlin 1
Brockport 1
Calgary 1
Cedar Knolls 1
Central 1
Clearwater 1
Council Bluffs 1
Dalian 1
Decatur 1
East Orange 1
Foshan 1
Frankfurt Am Main 1
Frankfurt am Main 1
Grenoble 1
Groningen 1
Gyeryong 1
Haidian 1
Hangzhou 1
Hefei 1
Helsinki 1
Henderson 1
Higashinippori 1
Hobart 1
Istanbul 1
Ivrea 1
Jacksonville 1
Kazan' 1
Kirkland 1
Lake Forest 1
Leeuwarden 1
Lexington 1
León 1
London 1
Los Angeles 1
Muizenberg 1
Murcia 1
Neckartenzlingen 1
Nice 1
Palo Alto 1
Pune 1
Ragusa 1
Rozzano 1
Saint-Sébastien-sur-Loire 1
Salò 1
San Jose 1
San Marcos 1
San Sebastián de los Reyes 1
Shenzhen 1
Sibiu 1
Totale 308
Nome #
Experience with regorafenib in the treatment of hepatocellular carcinoma, file e1dcb339-0004-7715-e053-1705fe0a6cc9 140
Circulating microRNAs, MIR-939, MIR-595, MIR-519d and MIR-494, identify cirrhotic patients with HCC, file e1dcb32d-8fd4-7715-e053-1705fe0a6cc9 95
Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma, file e1dcb32d-1b3e-7715-e053-1705fe0a6cc9 87
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma, file e1dcb337-9a4e-7715-e053-1705fe0a6cc9 77
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study, file e1dcb338-38aa-7715-e053-1705fe0a6cc9 31
Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC, file f5a942b2-3275-42c5-9aa4-4273688464dd 6
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study., file e1dcb32e-8b8a-7715-e053-1705fe0a6cc9 5
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study, file e1dcb339-f327-7715-e053-1705fe0a6cc9 3
Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases., file e1dcb32d-22dd-7715-e053-1705fe0a6cc9 2
Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma., file e1dcb32d-1ccb-7715-e053-1705fe0a6cc9 1
null, file e1dcb32d-bb7f-7715-e053-1705fe0a6cc9 1
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis, file e1dcb330-306f-7715-e053-1705fe0a6cc9 1
Totale 449
Categoria #
all - tutte 1.374
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.374


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191 0 0 0 0 0 0 0 0 0 0 0 1
2019/202051 0 0 0 4 6 5 7 9 9 4 3 4
2020/202143 3 2 2 1 6 4 4 3 2 9 3 4
2021/202276 3 6 3 4 6 2 5 3 0 12 23 9
2022/2023127 4 4 18 13 7 3 4 10 22 12 18 12
2023/2024145 9 6 14 15 13 16 19 8 18 20 7 0
Totale 449